Open AccessEltrombopag treatment of a dog with idiopathic aplastic pancytopenia
Author(s) -
Kelly Darren,
Lamb Valerie,
Juvet Florence
Publication year - 2020
Publication title -
journal of veterinary internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.356
H-Index - 103
eISSN - 1939-1676
pISSN - 0891-6640
DOI - 10.1111/jvim.15738
Subject(s) - eltrombopag , pancytopenia , medicine , thrombopoietin receptor , aplastic anemia , immunosuppression , prednisolone , gastroenterology , thrombopoietin , pediatrics , surgery , immune thrombocytopenia , platelet , haematopoiesis , bone marrow , genetics , stem cell , biology
Idiopathic aplastic pancytopenia is an uncommon disease in dogs which results in pancytopenia and for which an immune‐mediated etiology is suspected. A small number of affected dogs reported in the veterinary literature have responded to immunosuppressive medication but the prognosis generally is considered poor with a reported mortality rate of 80%. Reported response rates to immunosuppression alone in affected people are low with overall and complete responses of 65 and 10%, respectively. With the addition of eltrombopag, an orally available thrombopoietin receptor agonist, reported overall and complete response rates in people increase to 94 and 58%, respectively. Herein, we report the use of eltrombopag in a dog with idiopathic aplastic pancytopenia. Eltrombopag was started after no response was seen to treatment with prednisolone and cyclosporine. Complete remission was achieved after the addition of eltrombopag and was sustained after stopping the medication.